{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T02:35:49Z","timestamp":1769308549690,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ad.2025.104487","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:05:59Z","timestamp":1764691559000},"page":"104487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older"],"prefix":"10.1016","volume":"117","author":[{"given":"S.","family":"Va\u00f1\u00f3-Galv\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Figueras-Nart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-154X","authenticated-orcid":false,"given":"M.P.","family":"Fortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Herrera-Lasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Botella-Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.104487_bib0170","first-page":"e404","article-title":"Alopecia areata. Current situation and perspectives","volume":"115","author":"Ju\u00e1rez-Rend\u00f3n","year":"2017","journal-title":"Arch Argent Pediatr"},{"key":"10.1016\/j.ad.2025.104487_bib0175","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/12034754231168839","article-title":"Alopecia areata: an updated review for 2023","volume":"27","author":"Sibbald","year":"2023","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2025.104487_bib0180","first-page":"397","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Villasante Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.ad.2025.104487_bib0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/ijt.ijt_28_21","article-title":"An updated review on current treatment of alopecia areata and newer therapeutic options","volume":"15","author":"Malhotra","year":"2023","journal-title":"Int J Trichology"},{"key":"10.1016\/j.ad.2025.104487_bib0190","first-page":"59","article-title":"Alopecia areata \u2013 current understanding and management","volume":"20","author":"Lintzeri","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ad.2025.104487_bib0195","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1111\/jdv.16727","article-title":"Comorbidities in pediatric alopecia areata","volume":"34","author":"Conic","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104487_bib0200","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2147\/DDDT.S172638","article-title":"Role of janus kinase inhibitors in the treatment of alopecia areata","volume":"12","author":"Triyangkulsri","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"10387","key":"10.1016\/j.ad.2025.104487_bib0205","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2025.104487_bib0210","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.104487_bib0215","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/DDDT.S334727","article-title":"Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata","volume":"16","author":"Ram\u00edrez-Mar\u00edn","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ad.2025.104487_bib0220","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jcph.2347","article-title":"Target occupancy and functional inhibition of JAK3 and TEC family kinases by ritlecitinib in healthy adults: an open-label, phase 1 study","volume":"64","author":"Martin","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ad.2025.104487_bib0225","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.ad.2025.104487_bib0230","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nm.3685","article-title":"Inhibiting Janus kinases to treat alopecia areata","volume":"20","author":"Divito","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.ad.2025.104487_bib0235","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.ad.2025.104487_bib0240","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.142205","article-title":"Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata","volume":"6","author":"Dai","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ad.2025.104487_bib0245","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/jdv.20372","article-title":"Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata","volume":"39","author":"Aceituno","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104487_bib0250","unstructured":"European Medicines Agency [Internet]. Summary of product characteristics: Liftulo. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/litfulo-epar-product-information_en.pdf. Accessed 2 2024."},{"key":"10.1016\/j.ad.2025.104487_bib0255","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104487_bib0260","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104487_bib0265","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/jdv.20547","article-title":"Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme","volume":"39","author":"King","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104487_bib0270","article-title":"Efficacy of ritlecitinib (PF-06651600) in patients with alopecia totalis and alopecia universalis: post hoc analysis of the ALLEGRO phase 2b\/3 study","volume":"6","author":"Zhang","year":"2022","journal-title":"Skin J Cutan Med"},{"key":"10.1016\/j.ad.2025.104487_bib0275","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/pde.15378","article-title":"Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial","volume":"40","author":"Hordinsky","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2025.104487_bib0280","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/pde.15895","article-title":"A phase 1 open-label study of the pharmacokinetics of ritlecitinib in children aged 6\u201312 years with alopecia areata","volume":"42","author":"Gonzalez","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2025.104487_bib0285","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s13555-024-01260-7","article-title":"Impact of previous alopecia areata treatment on efficacy responses up to week 48 following ritlecitinib treatment: a post hoc analysis","volume":"14","author":"Fu","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2025.104487_bib0290","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO Clinical Trial Program","volume":"25","author":"King","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.104487_bib0295","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s13555-023-00937-9","article-title":"Incidence rates of infections, malignancies, thromboembolism, and cardiovascular events in an alopecia areata cohort from a US claims database","volume":"13","author":"George","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"s1","key":"10.1016\/j.ad.2025.104487_bib0300","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ad.2025.104487_bib0305","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrrheum.2017.51","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ad.2025.104487_bib0310","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.104487_bib0315","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.ad.2025.104487_bib0320","series-title":"FDA Requires Warnings About Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death for JAK Inhibitors that treat Certain Chronic Inflammatory Conditions","year":"2021"},{"key":"10.1016\/j.ad.2025.104487_bib0325","series-title":"Presented at American Academy of Dermatology","article-title":"Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials and contextualization with a US cohort of patients with AA","author":"Lo Sicco","year":"2024"},{"key":"10.1016\/j.ad.2025.104487_bib0330","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jdv.19768","article-title":"European expert consensus statement on the systemic treatment of alopecia areata","volume":"38","author":"Rudnicka","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025007562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025007562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T13:32:14Z","timestamp":1769261534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025007562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0001731025007562"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.104487","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.104487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of AEDV.","name":"copyright","label":"Copyright"}],"article-number":"104487"}}